Last reviewed · How we verify
BXCL701 monotherapy — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
BXCL701 monotherapy (BXCL701 monotherapy) — BioXcel Therapeutics Inc.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| BXCL701 monotherapy TARGET | BXCL701 monotherapy | BioXcel Therapeutics Inc | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- BXCL701 monotherapy CI watch — RSS
- BXCL701 monotherapy CI watch — Atom
- BXCL701 monotherapy CI watch — JSON
- BXCL701 monotherapy alone — RSS
Cite this brief
Drug Landscape (2026). BXCL701 monotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/bxcl701-monotherapy. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing